

DI-087: Drug use evaluation: Effectiveness, safety and cost of emtricitabine/tenofovir/rilpivirine



19th Congress of the EAHP, Barcelona (Spain), 2014 March

Ruiz-Darbons, S.I.(1)*; Herraiz Robles, P.(1); Esplá González, S.(1); Pons Martínez, L.(1); Bonete Sánchez, M.(1); Bujaldón Querejeta, N.(1); Jover Díaz, F.(2); Talens Bolos, A.(1); Aznar Saliente, T.(1); Martínez Ramírez, M.(1);
 (1) HOSPITAL SAN JUAN DE ALICANTE, PHARMACY SERVICE, Alicante, Spain;
 (2) HOSPITAL SAN JUAN DE ALICANTE, INFECTIOUS DISEASES DEPARTMENT, Alicante, Spain;

Objective

To assess the effectiveness, safety and cost of treatment with Eviplera® in naïve and pretreated patients

Materials and methods

- Observational retrospective study of 48 patients
- Effectiveness was considered to be achieved when:
 - A decrease in viral load was observed in naïve patients
 - The viral load was maintained lower than two logarithms in pretreated patients
- Telephone interviews were conducted to know all the side effects been experienced
- The annual cost by patient of Emtricitabine/Tenofovir/Rilpivirine was compared to the cost with the previous treatment in the case of pretreated patients


Results

- 48 patients were assessed: 10 naïve and 38 pretreated
- Data of effectiveness and safety were only available in 21 and 33 patients respectively
- Emtricitabine/Tenofovir/Rilpivirine seemed to be effective in 100% of patients and 42% of patients experienced some side effect

EFFECTIVENESS


SAFETY

NAÏVE PATIENTS VIRAL LOAD (VL) EVOLUTION




NAÏVE PATIENTS

MOST FREQUENT SIDE EFFECTS




OTHER SIDE EFFECTS (24%)




COST

MEDIAN ANUAL SAVE BY PATIENT IN PRETREATED PATIENTS




MEDIAN ANUAL SAVE BY PATIENT = 1463 EUROS

PRETREATED PATIENTS VIRAL LOAD (VL) EVOLUTION



PRETREATED PATIENTS

MEDIAN INCREASE OF CD4 LYMPHOCYTES VALUE



MEDIAN INCREASE = 106

Conclusion

- Emtricitabine/Tenofovir/Rilpivirine seems to be a cost-effective combination of antiretroviral drugs in treatment of HIV-1 naïve or pretreated patients
- It has been shown that patients may experience adverse events but these are mild in the most of cases
- Further studies should be carried out with longer periods of follow-up before a conclusion could be reached